Linoladiol N

Estradiol hemihydrate, the active ingredient in Linoladiol N, is an estrogen presented as a vaginal formulation for local hormone replacement therapy. It is used to alleviate estrogen deficiency symptoms in women, particularly during menopause or after oophorectomy.

GNH USA supplies Linoladiol N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Estradiol hemihydrate is employed in estrogen‑deficiency states and related conditions, acting through systemic and local estrogen pathways. - Menopausal symptoms: reduces hot flashes, vaginal dryness, and discomfort. - Hypoestrogenism due to ovarian failure: restores physiological estrogen levels. - Postmenopausal osteoporosis prevention: helps maintain bone mineral density.

Estradiol hemihydrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Vaginal irritation or discharge. - Headache. - Nausea. - Breast tenderness.

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism). - Stroke or myocardial infarction. - Endometrial hyperplasia or carcinoma. - Severe allergic reaction (anaphylaxis).

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and follow safe handling guidelines. - Assess cardiovascular risk: review history of clotting disorders or thromboembolic disease. - Screen for estrogen‑sensitive cancers: avoid use in active breast, ovarian, or uterine cancer. - Monitor liver function: adjust or discontinue if hepatic impairment is present. - Avoid concomitant use with progestins unless clinically indicated. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Estradiol hemihydrate can interact with several medications, altering efficacy or safety.

Major Interactions (Avoid): - Combined oral contraceptives: increased risk of thrombotic events. - Hormone therapy with progestins: heightened estrogen exposure. - Anticoagulants (e.g., warfarin): potential alteration of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may reduce estrogen efficacy. - Tamoxifen: antagonistic effect on estrogen receptors.